BIOMARIN PHARMACEUTICAL INC Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31)
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) of $1.60 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-04-29.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax · last filed 2013-04-29
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $1.60M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $183.00K.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2012-09-30 was -$3.00M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2012 was $3.68M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2011 was -$2.99M, a 170.98% decline from fiscal 2010.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2010 was $4.21M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2013-03-31 | $1.60M 10-Q · filed 2013-04-29 | $1.78M derived: sum of 2 quarters · filed 2013-04-29 | -$1.22M derived: sum of 3 quarters · filed 2013-04-29 | |
| 2012-12-31 | $183.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$2.82M derived: sum of 2 quarters · filed 2013-02-26 | $3.68M 10-K · filed 2013-02-26 | |
| 2012-09-30 | -$3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-29 | $3.50M 10-Q · filed 2012-10-29 | ||
| 2012-06-30 | $6.50M 10-Q · filed 2012-08-02 | |||
| 2011-12-31 | -$2.99M 10-K · filed 2013-02-26 | |||
| 2010-12-31 | $4.21M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |